{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:45:19Z","timestamp":1767134719367,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd004773.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000}}],"reference-count":69,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004773.pub3","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T03:21:39Z","timestamp":1535599299000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people"],"prefix":"10.1002","volume":"2018","author":[{"given":"Ajibola A","family":"Awotiwon","sequence":"first","affiliation":[{"name":"Knowledge Translation Unit, University of Cape Town Lung Institute; George street Observatory, Cape Town Western Cape South Africa 7700"},{"name":"Stellenbosch University; Centre for Evidence Based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences; Cape Town South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Johnson","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Pembroke Place Liverpool UK L3 5QA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W","family":"Rutherford","sequence":"additional","affiliation":[{"name":"University of California, San Francisco; Global Health Sciences; 550 16th Street Box 1224 San Francisco California USA 94143-1224"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[{"name":"University of Cape Town; Department of Medicine; Cape Town South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Eshun-Wilson","sequence":"additional","affiliation":[{"name":"Stellenbosch University; Centre for Evidence Based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences; Cape Town South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,29]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/338154","article-title":"A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand","volume":"34","author":"Chariyalertsak","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004773.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1468-1293.2004.00201.x","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency","volume":"5","author":"Chetchotisakd","year":"2004","journal-title":"HIV Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004773.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1086\/497373","article-title":"A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323\/Mycoses Study Group Study 40","volume":"41","author":"Goldman","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0004|cit4","unstructured":"NCT00000951 A study to compare the use of fluconazole as continuous therapy versus periodic therapy in HIV-positive patients with recurrent thrush clinicaltrials.gov\/ct2\/show\/NCT00000951"},{"issue":"3","key":"10.1002\/14651858.CD004773.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa","volume":"377","author":"Hakim","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0006|cit6","unstructured":"ISRCTN43622374 Reduction of early mortality in HIV-infected African adults and children starting antiretroviral therapy isrctn.com\/ISRCTN43622374"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1128\/AAC.44.6.1585-1587.2000","article-title":"Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group","volume":"44","author":"Goldman","year":"2000","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/mmy.39.2.207.213","article-title":"DNA fingerprinting of serial Candida albicans isolates obtained during itraconazole prophylaxis in patients with AIDS","volume":"39","author":"Monte","year":"2001","journal-title":"Medical Mycology"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/514744","article-title":"Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"28","author":"McKinsey","year":"1999","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0010|cit10","unstructured":"ISRCTN76481529 Primary prevention of invasive cryptococcal disease using fluconazole prophylaxis in Human Immunodeficiency Virus (HIV) infected Ugandans isrctn.com\/ISRCTN76481529"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0011|cit11","first-page":"8","article-title":"Successful primary prevention of cryptococcal disease using fluconazole prophylaxis in HIV-infected Ugandan adults (cryptopro): o26","volume":"10","author":"Parkes-Ratanshi","year":"2009","journal-title":"HIV Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004773.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1473-3099(11)70245-6","article-title":"Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial","volume":"11","author":"Parkes-Ratanshi","year":"2011","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9343(98)00137-5","article-title":"A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance","volume":"1","author":"Revankar","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004773.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-126-9-199705010-00003","article-title":"Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS","volume":"126","author":"Schuman","year":"1997","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004773.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/322641","article-title":"Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis","volume":"33","author":"Vazquez","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1086\/514746","article-title":"Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA)","volume":"28","author":"Vazquez","year":"1999","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1468-1293.2001.00060.x","article-title":"A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection","volume":"2","author":"Smith","year":"2001","journal-title":"HIV Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0018|cit18","first-page":"67","article-title":"Fluconazole may have edge in preventing infections","volume":"10","author":"Anonymous","year":"1995","journal-title":"AIDS Alert"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0019|cit19","first-page":"15","article-title":"Antifungal drug fluconazole found to be effective in preventing thrush in people who are HIV positive","volume":"250","author":"Anonymous","year":"2001","journal-title":"AHRQ Research Activities"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/QAI.0b013e31815bad0c","article-title":"The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species","volume":"47","author":"Apisarnthanarak","year":"2008","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/157016211797635991","article-title":"Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand","volume":"9","author":"Chaiwarith","year":"2011","journal-title":"Curr HIV Research"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/apc.2012.0303","article-title":"Discontinuation of primary and secondary prophylaxis for opportunistic infections in HIV-infected patients who had CD4+ cell count 3 but undetectable plasma HIV-1 RNA: an open-label randomized controlled trial","volume":"27","author":"Chaiwarith","year":"2013","journal-title":"AIDS Patient Care and STDs"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.40.6.1338","article-title":"Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women","volume":"40","author":"Geletko","year":"1996","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/515018","article-title":"Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS","volume":"27","author":"Havlir","year":"1998","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD004773.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/BF02005444","article-title":"Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients","volume":"10","author":"J\u00fcst-Nubling","year":"1991","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD004773.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archinte.1997.00440220068009","article-title":"Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection","volume":"157","author":"Manfredi","year":"1997","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2334-5-67","article-title":"Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study","volume":"5","author":"Manosuthi","year":"2005","journal-title":"BMC Infect Diseases"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0028|cit28","first-page":"795","article-title":"Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with\/without fluconazole prophylaxis","volume":"89","author":"Manosuthi","year":"2006","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"9983","key":"10.1002\/14651858.CD004773.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","article-title":"Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial","volume":"385","author":"Mfinanga","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD004773.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"e13856","DOI":"10.1371\/journal.pone.0013856","article-title":"Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia","volume":"5","author":"Micol","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1086\/515017","article-title":"Editorial response: Antifungal prophylaxis with weekly fluconazole for patients with AIDS","volume":"27","author":"Mylonakis","year":"1998","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004773.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ajhp\/55.3.279","article-title":"Preventing and treating azole-resistant oropharyngeal candidiasis in HIV-infected patients","volume":"55","author":"Penzak","year":"1998","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"11","key":"10.1002\/14651858.CD004773.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJM199503163321102","article-title":"A randomised trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"Powderly","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/clinids\/23.6.1282","article-title":"Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of \u2264 100\/mm\u00b3: demonstration of efficacy in a positive, multicenter trial","volume":"23","author":"Singh","year":"1996","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD004773.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/archinte.1991.00400120096018","article-title":"Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily","volume":"151","author":"Stevens","year":"1991","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02260343","article-title":"Prophylaxis of opportunistic infections in HIV infection","volume":"20","author":"Svoboda","year":"1995","journal-title":"Journal of Community Health"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/tropej\/fmn072","article-title":"Evidence behind the WHO guidelines: Hospital Care for Children: the usefulness of azole prophylaxis against cryptococcal meningitis in HIV-positive children","volume":"54","author":"Thurey","year":"2008","journal-title":"Journal of Tropical Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jac\/dkp451","article-title":"Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans","volume":"65","author":"Wakeham","year":"2010","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00001432-199312000-00005","article-title":"Antifungal prophylaxis","volume":"6","author":"White","year":"1993","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0040|cit40","first-page":"112","article-title":"Preventing mucosal candidiasis in HIV-infected women","volume":"30","author":"Anonymous","year":"1998","journal-title":"Emergency Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1742-1241.1999.tb11744.x","article-title":"A randomised, double-blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection","volume":"53","author":"Smith","year":"1999","journal-title":"International Journal of Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1468-1293.2008.00562.x","article-title":"Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand","volume":"9","author":"Apisarnthanarak","year":"2008","journal-title":"HIV Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jinf.2006.11.017","article-title":"Risk of resistance associated with fluconazole prophylaxis: systematic review","volume":"54","author":"Brion","year":"2007","journal-title":"Journal of Infection"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0044|cit44","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults Adolescents Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America Available at aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf"},{"issue":"3","key":"10.1002\/14651858.CD004773.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/13693786.2012.715763","article-title":"Fluconazole resistance in cryptococcal disease: emerging or intrinsic?","volume":"51","author":"Cheong","year":"2013","journal-title":"Medical Mycology"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0046|cit46","unstructured":"DAIDS Grading Table Working Group Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 2.0. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services. November 2014 Available from rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014.pdf"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0047|cit47","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0048|cit48","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0049|cit49","unstructured":"Liverpool HIV drug interactions HIV drug interaction checker www.hiv-druginteractions.org\/checker"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2334-10-67","article-title":"Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases","volume":"10","author":"Jarvis","year":"2010","journal-title":"BMC Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD004773.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1086\/587667","article-title":"Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy","volume":"46","author":"Kambugu","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"9312","key":"10.1002\/14651858.CD004773.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(02)08162-X","article-title":"Antifungal drug resistance of pathogenic fungi","volume":"359","author":"Kontoyiannis","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004773.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7196\/SAMJ.4378","article-title":"Poor long-term outcomes for cryptococcal meningitis in rural South Africa","volume":"101","author":"Lessells","year":"2011","journal-title":"South African Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD004773.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2125.1996.03085.x","article-title":"Pharmacokinetics of fluconazole in people with HIV infection: a population analysis","volume":"41","author":"McLachlan","year":"1996","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/368091","article-title":"The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000","volume":"36","author":"Mirza","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004773.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14656566.1.2.287","article-title":"Itraconazole","volume":"1","author":"Pierard","year":"2000","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD004773.pub3-BIB0057|cit57","first-page":"561","article-title":"Overview of treatment options for invasive fungal infections","volume":"49","author":"Pound","year":"2011","journal-title":"Medical Mycology"},{"issue":"8","key":"10.1002\/14651858.CD004773.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0059|cit59","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"7","key":"10.1002\/14651858.CD004773.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ccm.2017.04.007","article-title":"Cryptococcal lung infections","volume":"38","author":"Skolnik","year":"2017","journal-title":"Clinical Chest Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004773.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2217\/fvl.13.71","article-title":"Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis","volume":"8","author":"Ssekitoleko","year":"2013","journal-title":"Future Virology"},{"issue":"5","key":"10.1002\/14651858.CD004773.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/cid\/cix430","article-title":"Advanced HIV disease in Botswana following successful antiretroviral therapy rollout: incidence of and temporal trends in cryptococcal meningitis","volume":"65","author":"Tenforde","year":"2017","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD004773.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1093\/cid\/ciu057","article-title":"Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type B vaccination, 2000-2012","volume":"58","author":"Wall","year":"2014","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0065|cit65","unstructured":"World Health Organization Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children: World Health Organization. December 2011 Available from apps.who.int\/iris\/bitstream\/handle\/10665\/44786\/9789241502979_eng.pdf?sequence=1"},{"key":"10.1002\/14651858.CD004773.pub3-BIB0066|cit66","unstructured":"World Health Organization Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd edition. World Health Organization. 2016 Available from apps.who.int\/iris\/bitstream\/handle\/10665\/208825\/9789241549684_eng.pdf?sequence=1"},{"issue":"1","key":"10.1002\/14651858.CD004773.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2016.167","article-title":"Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy","volume":"13","author":"Williamson","year":"2017","journal-title":"Nature Reviews. Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004773.pub3-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004773","article-title":"Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV","author":"Chang","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004773.pub3-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004773.pub2","article-title":"Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV","author":"Chang","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004773.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T14:15:49Z","timestamp":1693836949000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004773.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":69,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004773.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]}}}